Cost-effectiveness and cost-utility of selective serotonin reuptake inhibitors, serotonin norepinephrine reuptake inhibitors, and tricyclic antidepressants in depression with comorbid cardiovascular disease
Resource
J. Psychiatr. Res., 54, 70-78
Journal
Journal of Psychiatric Research
Pages
70-78
Date Issued
2014
Date
2014
Author(s)
Pan, Yi-Ju
Kuo, Kuei-Hong
Chan, Hung-Yu
McCrone, Paul
Abstract
Objective: There is a lack of clarity in the literature regarding the cost-effectiveness and cost-utility of antidepressants for treating real-world patients. The impact of comorbid cardiovascular disease (CVD) on the economic evaluations of antidepressants remains to be determined.
Method: Adult patients prescribed with antidepressants for depression were identified from the National Health Insurance Research Database in Taiwan. A cost-effectiveness and cost-utility analysis was conducted comparing selective serotonin reuptake inhibitors (SSRIs), serotonin norepinephrine reuptake inhibitors (SNRIs), and tricyclic antidepressants (TCAs), and by the presence of comorbid CVD.
Results: In terms of treatment success rates, SSRIs were the most cost-effective option compared to TCAs and SNRIs as revealed in the incremental cost-effectiveness ratios. The cost-effectiveness acceptability curves further showed differential findings in the cost-utility results by the presence of comorbid CVD.
Conclusion: To improve treatment success rates and quality-adjusted life years, SSRIs can be considered the most cost-effective option. Future research is needed to further clarify the impacts of physical comorbidities and other associated factors on the cost-effectiveness and cost-utility of pharmacological treatments in patients with depression. (C) 2014 Elsevier Ltd. All rights reserved.
Subjects
Depression
Cardiovascular disease
Antidepressant
Cost-effectiveness
Cost-utility
SDGs
Other Subjects
serotonin noradrenalin reuptake inhibitor; serotonin uptake inhibitor; tricyclic antidepressant agent; antidepressant agent; serotonin uptake inhibitor; adult; article; cardiovascular disease; comorbidity; cost effectiveness analysis; cost utility analysis; data base; depression; drug cost; economic evaluation; female; human; major clinical study; male; national health insurance; prescription; priority journal; quality adjusted life year; Taiwan; treatment outcome; adolescent; aged; analysis of variance; Cardiovascular Diseases; cost benefit analysis; depression; economics; information processing; middle aged; public health; sensitivity and specificity; statistics and numerical data; young adult; Adolescent; Adult; Aged; Analysis of Variance; Antidepressive Agents; Cardiovascular Diseases; Cost-Benefit Analysis; Datasets as Topic; Depression; Female; Humans; Male; Middle Aged; National Health Programs; Quality-Adjusted Life Years; Sensitivity and Specificity; Serotonin Uptake Inhibitors; Taiwan; Treatment Outcome; Young Adult